PL1902141T3 - Kompozycje o działaniu trombolitycznym zawierające ADAMTS13 - Google Patents

Kompozycje o działaniu trombolitycznym zawierające ADAMTS13

Info

Publication number
PL1902141T3
PL1902141T3 PL06754405T PL06754405T PL1902141T3 PL 1902141 T3 PL1902141 T3 PL 1902141T3 PL 06754405 T PL06754405 T PL 06754405T PL 06754405 T PL06754405 T PL 06754405T PL 1902141 T3 PL1902141 T3 PL 1902141T3
Authority
PL
Poland
Prior art keywords
adamts13
thrombus
compositions
thrombolytic activity
disintegrating
Prior art date
Application number
PL06754405T
Other languages
English (en)
Inventor
Denisa Wagner
Anil Kumar Chauhan
Friedrich Scheiflinger
Barbara Plaimauer
Original Assignee
Baxalta Inc
Baxalta GmbH
Immune Disease Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc, Baxalta GmbH, Immune Disease Inst Inc filed Critical Baxalta Inc
Publication of PL1902141T3 publication Critical patent/PL1902141T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL06754405T 2005-06-17 2006-06-16 Kompozycje o działaniu trombolitycznym zawierające ADAMTS13 PL1902141T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69192705P 2005-06-17 2005-06-17
US72932305P 2005-10-21 2005-10-21
US77126506P 2006-02-07 2006-02-07
PCT/EP2006/005800 WO2006133955A1 (en) 2005-06-17 2006-06-16 Adamts13-comprising compositions having thrombolytic activity
EP06754405A EP1902141B1 (en) 2005-06-17 2006-06-16 Adamts13-comprising compositions having thrombolytic activity

Publications (1)

Publication Number Publication Date
PL1902141T3 true PL1902141T3 (pl) 2012-12-31

Family

ID=36956096

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06754405T PL1902141T3 (pl) 2005-06-17 2006-06-16 Kompozycje o działaniu trombolitycznym zawierające ADAMTS13

Country Status (9)

Country Link
US (4) US20070015703A1 (pl)
EP (1) EP1902141B1 (pl)
AT (1) ATE544866T1 (pl)
AU (1) AU2006257073B2 (pl)
CA (1) CA2606351C (pl)
DK (1) DK1902141T3 (pl)
ES (1) ES2382104T3 (pl)
PL (1) PL1902141T3 (pl)
WO (1) WO2006133955A1 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
PL1902141T3 (pl) 2005-06-17 2012-12-31 Baxalta Inc Kompozycje o działaniu trombolitycznym zawierające ADAMTS13
FR2918375B1 (fr) 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
AU2009246603B8 (en) * 2008-05-12 2015-08-13 Children's Medical Center Corporation von Willebrand Factor (VWF) inhibitors for treatment or prevention of infarction
ES2713270T3 (es) * 2008-10-27 2019-05-20 Baxalta GmbH Modelos de ratón de púrpura trombocitopénica trombótica y métodos para su uso
EP3388529A1 (en) 2008-12-05 2018-10-17 Baxalta GmbH Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof
JP5411582B2 (ja) * 2009-06-02 2014-02-12 一般財団法人化学及血清療法研究所 Ａｄａｍｔｓ１３による細胞移植増強補助剤
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
AU2010295299B2 (en) 2009-09-21 2015-12-24 Takeda Pharmaceutical Company Limited Stabilized liquid and lyophilized ADAMTS13 formulations
DK2488203T3 (en) * 2009-10-16 2017-03-13 Omeros Corp METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
KR20220044616A (ko) 2011-04-08 2022-04-08 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
CA2963288A1 (en) 2014-10-03 2016-04-07 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
CN105991563B (zh) * 2015-02-05 2020-07-03 阿里巴巴集团控股有限公司 一种保护敏感数据安全的方法、装置及三方服务系统
US10639307B2 (en) 2015-05-15 2020-05-05 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of preeclampsia comprising administration of ADAMTS13 polypeptides
AU2016334804B2 (en) 2015-10-09 2022-03-31 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
ES2983978T3 (es) 2016-01-08 2024-10-28 Univ Kyoto Medicina que comprende ADAMTS13 como ingrediente principal
KR20230079461A (ko) * 2016-08-04 2023-06-07 다케다 파머수티컬 컴패니 리미티드 급성 폐 손상 및/또는 급성 호흡 곤란 증후군에서 혈관폐색 위기의 치료, 개선 및/또는 예방을 위한 adamts13의 용도
LT3673080T (lt) 2017-08-25 2023-12-27 Stoke Therapeutics, Inc. Priešprasminiai oligomerai, skirti būklėms ir ligoms gydyti
BR112020022512A2 (pt) 2018-05-04 2021-05-04 Stoke Therapeutics, Inc. métodos e composições para tratamento de doença de armazenamento de éster de colesteril
EP4037704B1 (en) * 2019-10-04 2025-12-03 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
WO2021198781A2 (en) 2020-04-02 2021-10-07 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
EP4150092A4 (en) 2020-05-11 2024-11-06 Stoke Therapeutics, Inc. OPA1 ANTISENSE OLIGOMERS FOR THE TREATMENT OF DISEASES AND CONDITIONS
JP2023526546A (ja) 2020-05-22 2023-06-21 武田薬品工業株式会社 コロナウイルス疾患の合併症の治療及び診断のための、ａｄａｍｔｓ１３組成物及び方法
IL302984A (en) * 2020-11-18 2023-07-01 Green Cross Corp Adamts13 variant having increased escaping rate or activity against autoantibody
KR20240112755A (ko) * 2023-01-11 2024-07-19 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5082218A (pl) * 1973-11-10 1975-07-03
US4791138A (en) * 1983-12-14 1988-12-13 The Upjohn Company Method for treating or preventing deep vein thrombosis using lipoxygenase inhibitors
ES2317843T3 (es) * 1999-07-13 2009-05-01 Bolder Biotechnology, Inc. Proteinas de fusion de eritropoyetina-inmunoglobulina.
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja) 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
US7037658B2 (en) * 2001-08-16 2006-05-02 Regents Of University Of Michigan Methods and compositions for detecting variant ADAMTS13 genes
US20030073115A1 (en) * 2002-09-16 2003-04-17 Shyam Ramakrishnan Regulation of human galanin receptor-like g protein coupled receptor
US7763430B2 (en) * 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
EP1568782A1 (de) * 2004-02-25 2005-08-31 Clemens Bockmeyer Diagnose und Therapie von ADAMTS-13 assoziierten Erkrankungen
PL1902141T3 (pl) 2005-06-17 2012-12-31 Baxalta Inc Kompozycje o działaniu trombolitycznym zawierające ADAMTS13

Also Published As

Publication number Publication date
AU2006257073B2 (en) 2011-08-04
US10233436B2 (en) 2019-03-19
US20130136732A1 (en) 2013-05-30
EP1902141B1 (en) 2012-02-08
WO2006133955A1 (en) 2006-12-21
DK1902141T3 (da) 2012-05-07
ES2382104T3 (es) 2012-06-05
EP1902141A1 (en) 2008-03-26
ATE544866T1 (de) 2012-02-15
AU2006257073A1 (en) 2006-12-21
US20220002703A1 (en) 2022-01-06
HK1118579A1 (en) 2009-02-13
WO2006133955A8 (en) 2007-11-29
CA2606351C (en) 2016-12-13
US11124787B2 (en) 2021-09-21
US20190161746A1 (en) 2019-05-30
CA2606351A1 (en) 2006-12-21
US20070015703A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
PL1902141T3 (pl) Kompozycje o działaniu trombolitycznym zawierające ADAMTS13
MX2012004551A (es) Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
WO2006124874A3 (en) Inhibitors of b-raf kinase
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
MX2009005527A (es) Metodos para el tratamiento de hipercolesterolemia.
TW200637522A (en) Skin treatment articles and methods
MY145070A (en) Imidazolothiazole compounds for the treatment of disease
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
TW200633980A (en) Pyridones useful as inhibitors of kinases
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
WO2007087151A3 (en) Combination of ache inhibitor and 5-ht6 antagonist for the treatment of cognitive dysfunction
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
MXPA05011858A (es) Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
TW200716204A (en) Pharmaceutical composition
WO2007130501A3 (en) Combination therapy for treatment of cancer
UA96926C2 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof